Hutchison China Meditech Limited Results of Annual General Meeting (4310M)

TIDMHCM

RNS Number : 4310M

Hutchison China Meditech Limited

27 April 2018

Results of Annual General Meeting

London: Friday, April 27, 2018: Hutchison China MediTech Limited ("Chi-Med") (AIM/Nasdaq: HCM) today announces that all ordinary resolutions and special resolutions put to its Annual General Meeting ("AGM") held on April 27, 2018 were duly passed. The poll results of the resolutions were as follows:

 
                                                                  Number of Votes (%)* 
 
   Resolutions                                               For          Against      Withheld(#) 
     To consider and adopt the 
      audited financial statements 
      and the reports of the 
      directors and independent 
      auditor for the year ended 
 1    31 December 2017.                                 43,747,211         230             0 
                                                        (99.99947%)     (0.00053%) 
 
     To re-elect Mr Simon To 
 2    as a director.                                    43,207,556       353,263        186,622 
                                                        (99.18903%)     (0.81097%) 
 
     To re-elect Mr Christian 
 3    Hogg as a director.                               43,742,340        4,901           200 
                                                        (99.98880%)     (0.01120%) 
 
     To re-elect Professor Tony 
 4    Mok as a director.                                43,747,241          0             200 
                                                        (100.00000%)    (0.00000%) 
 
     To re-elect Ms Edith Shih 
 5    as a director.                                    43,742,310        4,931           200 
                                                        (99.98873%)     (0.01127%) 
 
     To re-appoint PricewaterhouseCoopers 
      as the auditor of the Company 
      and authorise the board 
      of directors to fix the 
 6    auditor's remuneration.                           43,747,211         230             0 
                                                        (99.99947%)     (0.00053%) 
 
                               To grant 
                                a general 
                                mandate to 
                                the directors 
                                of the Company 
                                to issue 
     Ordinary Resolution        additional 
 7    No. 7(A)             :    shares.                 43,746,866         575             0 
                                                        (99.99869%)     (0.00131%) 
 
                               To disapply 
                                pre-emption 
     Special Resolution         rights (general 
      No. 7(B)             :    power).                 42,520,006       552,895        674,540 
                                                        (98.71637%)     (1.28363%) 
 
                               To disapply 
                                pre-emption 
                                rights (in 
                                connection 
                                with an acquisition 
     Special Resolution         or specified 
      No. 7(C)             :    capital investment).    41,723,007      1,349,894       674,540 
                                                        (96.86602%)     (3.13398%) 
 
                               To grant 
                                a general 
                                mandate to 
                                the directors 
                                of the Company 
                                to repurchase 
     Ordinary Resolution        shares of 
      No. 7(D)             :    the Company.            43,746,636         805             0 
                                                        (99.99816%)     (0.00184%) 
 

* Percentages rounded to 5 decimal places

(#) A vote withheld is not a vote in law and is not counted in the calculation of the proportion of the votes for and against a resolution.

As at the date of the AGM, the number of issued shares of Chi-Med was 66,484,620, which was the total number of shares entitling the holders to attend and vote on the ordinary resolutions and special resolutions proposed at the AGM.

About Chi-Med

Chi-Med is an innovative biopharmaceutical company which researches, develops, manufactures and sells pharmaceuticals and healthcare products. Its Innovation Platform, Hutchison MediPharma Limited, focuses on discovering and developing innovative therapeutics in oncology and autoimmune diseases for the global market. Its Commercial Platform manufactures, markets, and distributes prescription drugs and consumer health products in China.

Chi-Med is majority owned by the multinational conglomerate CK Hutchison Holdings Limited (SEHK: 1). For more information, please visit: www.chi-med.com.

CONTACTS

 
Investor Enquiries 
Mark Lee, Senior Vice President, Corporate Finance 
 & Development                                       [phone] 
 
U.K. & International Media Enquiries 
Anthony Carlisle, Citigate Dewe Rogerson             [phone] (Mobile)   [e-mail] 
 
U.S. Based Media Enquiries 
Brad Miles, BMC Communications                       [phone] (Mobile)  [e-mail] 
Susan Duffy, BMC Communications                      [phone] (Mobile)  [e-mail] 
 
Investor Relations 
Matt Beck, The Trout Group                           [phone] (Mobile)  [e-mail] 
David Dible, Citigate Dewe Rogerson                  [phone] (Mobile)   [e-mail] 
 
Panmure Gordon (UK) Limited 
Richard Gray / Andrew Potts                          [phone] 
 

This information is provided by RNS

The company news service from the London Stock Exchange

END

RAGSESFEWFASEIL

(END) Dow Jones Newswires

April 27, 2018 08:52 ET (12:52 GMT)